

MS Pharma Group signs exclusive biosimilars collaboration agreement with Hetero

27 January 2026 | News

Significant step towards strengthening Algeria's biopharmaceutical ecosystem



MS Pharma Group, a leading regional pharmaceutical company in the Middle East and North Africa (MENA) region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localise five established biosimilars across key therapeutic areas, including oncology, immunology and hematology.

The exclusive agreement will be implemented through El Kendi – MS Pharma Group's affiliate in Algeria and Hetero Biopharma – a subsidiary of Hetero Group. This marks Hetero's first local partnership in the country, representing a significant step towards strengthening Algeria's biopharmaceutical ecosystem. The combined portfolio represents an estimated total market value of \$45 million in Algeria (2024) and will be executed through a localisation and technology transfer approach.

"Strategic partnerships like this enable us to build durable regional capabilities and create meaningful, long-term impact for patients and health systems across the MENA region," said Kalle Känd, CEO of MS Pharma.

"At Hetero, we are guided by a strong commitment to ensuring access to high-quality and affordable medicines for patients across the globe. We are pleased to enter into a strategic partnership with MS Pharma, a well-established and trusted healthcare leader in the Middle East and beyond. This collaboration marks an important step in advancing healthcare delivery and addressing unmet medical needs across the Middle East, Algeria, and other key markets", said Dr Vamsi Krishna, MD, Hetero Group.